Oncolinx (Boston, MA) is developing the next generation of antibody-drug conjugates (ADCs)–powerful, targeted cancer therapies that are more effective and have dramatically fewer side effects than current methods of cancer treatment.

Website : https://www.oncolinx.com/

Call 2017

Call for applications open.




Receive notifications about the YEi Start in France program (Call for applications, announcement of the laureates, YEi events, etc.)

Social Links